<DOC>
	<DOC>NCT01166217</DOC>
	<brief_summary>PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the relative bioavailability of three different oral dose formulations of PF-04620110.</brief_summary>
	<brief_title>A Single Dose Study Of PF-04620110 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 21 and 55 years Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Single Dose Study in Healthy Subjects</keyword>
</DOC>